Company Overview

India Globalization Capital, Inc. (IGC) is comprised of two lines of business: an infrastructure operation and a plant and cannabinoid operation — both of which are industry authorities and pioneers.  Our commitment to fostering partnerships allows us to execute powerful visions through innovation and dedication to excellence.

 

Infrastructure Business:

The depth of our team’s collective efforts is expansive, contracting infrastructure projects and renting equipment in India. We create and market new products and services, including but not limited to trading steel, iron ore and building materials in Hong Kong throughout South Asia. We provide premium customer service to the industries and businesses we serve.

Cannabis Based Pharmaceutical Business:

We are leaders and visionaries in developing plant-based therapies that are rooted in hard science. In 2013 we started exploring opportunities in the then nascent and emerging cannabis industry as a way to become a first mover in this exciting business segment.  We first established ourselves on the West Coast of the U.S. and set up operations in Washington State.  As we studied the industry, we learned everything from growing marijuana (indoor, outdoor, LED HPLC, organic, soil, & hydroponics) to extraction, testing, strain management, creating new hybrids, products like tincture, infused products, and many of the other subtleties. We recruited and enlisted some of the most experienced, knowledgeable and innovative individuals in the cannabis and other closely related industries like pharmaceuticals and natural products.

Our team has filed seven cannabis-based patents addressing various ailments and expect to make our most advanced and promising formulation, Hyalolex for Alzheimer’s, available to patients in Puerto Rico. Our formulation, Hyalolex, has been shown to address the primary indicators of Alzheimer’s, plaques and tangles, as well as alleviate several end points of the disease like anxiety and sleep disorders. Hyalolex achieves this without patients getting high, or suffering long-term damage to neurons.

 

Future Canna-Pharma Milestones

 

2018

Goal: Establish sales outlets for canna-pharmaceutical products

Expand the marketing of Hyalolex to 10 states in the U.S.

Expand the marketing of Hyalolex to Canada and Germany.

File ANDA with the FDA for Natrinol.

File FDA clinical trial for Hyalolex

Finalize Serosapse for Parkinson’s disease.

Introduce Serosapse into test markets.

File patents on two new products.

2019

Goal: Grow sales outlets for products

Expand Hyalolex and Serosapse to all medical cannabis states in the U.S.

Expand the marketing of Serosapse to Canada and Germany.

Expand Hyalolex and Serosapse to other countries (Colombia, Peru, UK…).

File clinical trials for Caesafin.

Commercialize two other products through medical dispensaries.

2020

Goal: Continue expansion of sales and marketing

Obtain FDA approval of ANDA for Natrinol.

Introduce Natrinol and approach insurance companies for coverage.

Expand markets for Hyalolex, Serosapse and Caesafin.

Expand product portfolio and strengthen the brand.

Our Story

2005

We were incorporated in 2005 as a Maryland, U.S.A corporation

Our filings are available free on www.sec.gov .

2008

In 2008, we entered the infrastructure industry in India with acquisitions of Techni Bharathi Private Limited (“TBL”) and Sricon Infrastructure.

Visit Techni Bharti Official Website here

2009

In early 2009, we expanded into the commodity business trading iron ore, cement, aggregate, and other materials.

2013

In late 2013 we expanded our infrastructure business into the U.S. targeting the cannabis industry. We evolved this business into cannabis-based pharmaceuticals.

2014

Our team developed and filed the first patent for the treatment of pain.

2015

Our team developed and filed a patent for treating epilepsy in cats and dogs.

Our team developed and filed a patent for treating eating disorders.

Our team developed and filed another patent for treating cancer and AIDS induced nausea, vomiting, and eating disorders.

2016

Our team developed and filed another patent for treating seizures

In February 2016, we acquired Cabaran Ultima Sdn. Bhd., a Malaysian real estate management company.

Ultima is an international real estate project management company with expertise in (i) building agro-infrastructure for growing medicinal plants and botanical extraction, (ii) construction of high-end luxury complexes such as service apartments, luxury condominiums and hotels, and (iii) design management of other large-scale infrastructure.

2017

Our team developed and filed another patent for treating eating disorders.

We acquired an exclusive license to a patent filed by the University of South Florida Research Foundation entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease”.

 

We are entrepreneurial, collegiate, data driven, analytical to the point that every thing is a model, serious about science, serious about helping people, and unrelenting in our pursuit. The breath and depth of our team’s collective knowledge is unrivaled.

Leadership

RichardPrins

Richard Prins

Chairman: Mr. Prins has served as our Chairman and Audit Committee Chairman since 2012 and has been a…

RamMukunda

Ram Mukunda

Chief Executive Officer: Mr. Mukunda, has served as our Executive Chairman, Chief Executive Officer, and President since the…

SudhakarShenoy-2

Sudhakar Shenoy

Director: Mr. Shenoy has been our Compensation Committee Chairman since 2012 and has served as a Director since…

JagadeeshRao

Dr. Jagadeesh Rao

Dr. Jagadeesh Rao has been our Chief of Science since October 2017. He has extensive experience working at…

CGrimaldi

Claudia Grimaldi

Vice President: Ms. Grimaldi is our Vice President and Principal Financial Officer. Before assuming her current role, as…

Dr.CraigCheifetz

Dr. Craig Cheifetz

Dr. Craig Cheifetz is an advisor to the company broadly in the areas of clinical trials, biotechnology, neuroscience,…

Loading blog posts...